Abstract
Purpose
Clinical practice guidelines recommend altering neurotoxic chemotherapy treatment in patients experiencing intolerable chemotherapy-induced peripheral neuropathy (CIPN). The primary objective of this survey was to understand patient’s perspectives on altering neurotoxic chemotherapy treatment, including their perceptions of the benefits of preventing irreversible CIPN and the risks of reducing treatment efficacy.
Methods
A cross-sectional online survey was distributed via social networks to patients who were currently receiving or had previously received neurotoxic chemotherapy for cancer. Survey results were analyzed using descriptive statistics and qualitative analysis.
Results
Following data cleaning, 447 participants were included in the analysis. The median age was 57 years, 93% were white, and most were from the UK (53%) or USA (38%). Most participants who were currently or recently treated expected some CIPN symptom resolution (86%), but 45% of those who had completed treatment more than a year ago reported experiencing no symptom resolution. Participants reported that they would discontinue chemotherapy treatment for less severe CIPN if they knew their symptoms would be permanent than if symptoms would disappear after treatment. Most patients stated that the decision to alter chemotherapy or not was usually made collaboratively between the patient and their treating clinician (61%). The most common reason participants were reluctant to talk with their clinician about CIPN was fear that treatment would be altered. Participants noted a need for improved understanding of CIPN symptoms and their permanence, better patient education relating to CIPN prior to and after treatment, and greater clinician understanding and empathy around CIPN.
Conclusions
This survey highlights the importance of shared decision-making, including a consideration of both the long-term benefits and risks of altering neurotoxic chemotherapy treatment due to CIPN. Additional work is needed to develop decision aids and other communication tools that can be used to improve shared decision making and help patients with cancer achieve their treatment goals.
Similar content being viewed by others
Data Availability
Survey data is available upon reasonable request to the corresponding author.
References
Alberti P, Salvalaggio A, Argyriou AA, Bruna J, Visentin A, Cavaletti G, Briani C (2022) Neurological complications of conventional and novel anticancer treatments. Cancers (Basel) 14(24):6088. https://doi.org/10.3390/cancers14246088
Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP et al (2019) Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19(1):132
Beijers AJ, Mols F, Tjan-Heijnen VC, Faber CG, van de Poll-Franse LV, Vreugdenhil G (2015) Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry. Acta Oncol 54(4):463–469
Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology 14(Suppl 4(Suppl 4)):iv45–iv54. https://doi.org/10.1093/neuonc/nos1203
Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S (2017) Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol 35(23):2604–2612
Engvall K, Gréen H, Fredrikson M, Lagerlund M, Lewin F, Åvall-Lundqvist E (2022) Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study. Breast Cancer Res Treat 195(3):379–391. https://doi.org/10.1007/s10549-022-06670-9 Epub 12022 Aug 10549
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M et al (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 20(12):3355–3364
Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31(21):2699–2707
Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R et al (2019) Patients’ and physicians’ interpretation of chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(1):111–119. https://doi.org/10.1111/jns.12306 Epub 12019 Feb 12308
Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL, 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA (2018) Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst 110:djx162. https://doi.org/10.1093/jnci/djx162
Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd et al (2018) Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). J Natl Cancer Inst
Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, Frigeni B, Cacciavillani M, Bergamo F, Cortinovis D et al (2014) Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst 19(4):299–306. https://doi.org/10.1111/jns.12097
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 14(10):01399
Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, Le Rhun E, Preusser M, Scotté F, Taphoorn MJB et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31(10):1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003 Epub 2020 Jul 1330
Cespedes Feliciano EM, Chen WY, Lee V, Albers KB, Prado CM, Alexeeff S, Xiao J, Shachar SS, Caan BJ (2020) Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer. JAMA Oncol 6(2):264–270. https://doi.org/10.1001/jamaoncol.2019.4668
Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G (2011) Evaluating the impact of relative total dose intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 11:131
de Morree ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M et al (2016) Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the Mainsail Study. JAMA Oncol
Tofthagen CS, McMillan SC, Kip KE (2011) Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs 34(4):E10–E20. https://doi.org/10.1097/NCC.1090b1013e31820251de
Obaid A, El-Aqoul A, Alafafsheh A, Abu-Khudair H, Saleh M, Kuliab A (2020) Validation of the arabic version of the chemotherapy-induced peripheral neuropathy assessment tool. Pain Manag Nurs 21:587–593. https://doi.org/10.1016/j.pmn.2020.05.005
Tofthagen C, Overcash J, Kip K (2012) Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer 20(3):583–589
Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL et al (2021) Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev 99:102241. https://doi.org/10.1016/j.ctrv.2021.102241
Salgado TM, Quinn CS, Krumbach EK, Wenceslao I, Gonzalez M, Reed HL, Syverson JG, Etz RS, Vangipuram K, Barker MR et al (2020) Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. Support Care Cancer 28(9):4163–4172. https://doi.org/10.1007/s00520-019-05254-6 Epub 02020 Jan 00522
Rocque GB, Rasool A, Williams BR, Wallace AS, Niranjan SJ, Halilova KI, Turkman YE, Ingram SA, Williams CP, Forero-Torres A, Smith T, Bhatia S, Knight SJ (2019) What is important when making treatment decisions in metastatic breast cancer? a qualitative analysis of decision-making in patients and oncologists. Oncologist 24:1313–1321. https://doi.org/10.1634/theoncologist.2018-0711
Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S et al (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142(1):101–107
Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, Sütterlin M (2018) Patient preferences regarding chemotherapy in metastatic breast cancer-a conjoint analysis for common taxanes. Front Oncol 8:535. https://doi.org/10.3389/fonc.2018.00535 eCollection 02018
Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A et al (2016) Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol 7(3):469–478. https://doi.org/10.21037/jgo.2016.01.03
Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):e234–e240
Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, Friedlander M, Goldstein D, Park SB (2021) Weekly paclitaxel-induced neurotoxicity in breast cancer: outcomes and dose response. Oncologist 1(10):13697
Brauer ER, Long EF, Melnikow J, Ravdin PM, Ganz PA (2019) Communicating risks of adjuvant chemotherapy for breast cancer: getting beyond the laundry list. J Oncol Pract 15(2):e98–e109. https://doi.org/10.1200/JOP.18.00162 Epub 02018 Dec 00114
Sanoff HK, Morris W, Mitcheltree AL, Wilson S, Lund JL (2015) Lack of support and information regarding long-term negative effects in survivors of rectal cancer. Clin J Oncol Nurs 19(4):444–448
Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R et al (2017) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 4(4):CD001431. https://doi.org/10.1002/14651858.CD001431.pub4
Bruera E, Willey JS, Palmer JL, Rosales M (2002) Treatment decisions for breast carcinoma: patient preferences and physician perceptions. Cancer 94(7):2076–2080
Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK (2002) Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA 288(23):3027–3034
Tariman JD, Berry DL, Cochrane B, Doorenbos A, Schepp KG (2012) Physician, patient, and contextual factors affecting treatment decisions in older adults with cancer and models of decision making: a literature review. Oncol Nurs Forum 39(1):E70–E83
van de Water LF, van Kleef JJ, WPM D, Henselmans I, van den Boorn HG, Vaarzon Morel NM, Schut KF, Daams JG, EMA S, van Laarhoven HWM (2020) Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods. Qual Life Res 29(7):1747–1766. https://doi.org/10.1007/s11136-020-02503-8 Epub 12020 Apr 11124
Licqurish SM, Cook OY, Pattuwage LP, Saunders C, Jefford M, Koczwara B, Johnson CE, Emery JD (2019) Tools to facilitate communication during physician-patient consultations in cancer care: an overview of systematic reviews. CA Cancer J Clin 69(6):497–520. https://doi.org/10.3322/caac.21573 Epub 22019 Jul 21524
Tanay MA, Armes J (2019) Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer. Eur J Cancer Care (Engl) 28(3):e13011. https://doi.org/10.1111/ecc.13011 Epub 12019 Feb 13020
Tanay MAL, Armes J, Ream E (2017) The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care (Engl) 26(5). https://doi.org/10.1111/ecc.12443
Richardson DR, Loh KP (2022) Improving personalized treatment decision-making for older adults with cancer: the necessity of eliciting patient preferences. J Geriatr Oncol 13(1):1–3. https://doi.org/10.1016/j.jgo.2021.1006.1001 Epub 2021 Jun 1011
Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85(4):392–398. https://doi.org/10.1136/jnnp-2013-305334 Epub 302013 Jun 305329
Alberti P, Rossi E, Argyriou AA, Kalofonos HP, Briani C, Cacciavillani M, Campagnolo M, Bruna J, Velasco R, Cazzaniga ME et al (2018) Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. Support Care Cancer 26(9):3143–3151. https://doi.org/10.1007/s00520-018-4170-9 Epub 02018 Mar 00529
Hawley ST (2018) Challenges to measuring and achieving shared decision-making in practice. Health Expect 21(1):1–2
Pratt-Chapman M, Moses J, Arem H (2021) Strategies for the identification and prevention of survey fraud: data analysis of a web-based survey. JMIR Cancer 7(3):e30730. https://doi.org/10.2196/30730
Acknowledgements
We would like to thank all survey respondents and organizations who helped with survey distribution, including Bowel Cancer UK and Myeloma UK. P.A. is supported by Bicocca Starting Grant (University of Milano-Bicocca).
Author information
Authors and Affiliations
Contributions
D.H, C.T., M.L, M.T. conceptualized the project and survey. M.C., K.S., L.N., L.G., D.V.A., S.M., K.R., A.C. helped with survey development and testing. E.R., D.B., and J.L. analyzed the data. D.H. wrote the main manuscript text and created the figures. All authors reviewed the manuscript and provided critical feedback.
Corresponding author
Ethics declarations
Ethics approval
This survey was approved by the Institutional Review Board of King’s College London (MRA-20/21-22971) and conducted in accordance with the Declaration of Helsinki.
Consent to participate and publish
Individuals consented to participate in the study within their responses to a dedicated survey question. No individual participant health information was published.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
ESM 1
Supplementary Table 1 Free Text Comments about CIPN (DOCX 17 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hertz, D.L., Tofthagen, C., Rossi, E. et al. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Support Care Cancer 32, 48 (2024). https://doi.org/10.1007/s00520-023-08209-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-023-08209-0